The CC chemokine receptor (CCR)4 is associated with trafficking of specialized cutaneous memory type 2 T h cells in the skin. However, a CD8
Introduction

CD8
+ T cells play an important role in the eradiation of viruses and tumors. When naive CD8
+ T cells encounter a foreign antigen in the context of MHC class 1, they divide and differentiate into large numbers of effector CD8 + cells, which exert their immune function by direct cytolysis and secretion of cytokines such as IFN-c and tumor necrosis factor (TNF)-a (1, 2) . This population of cells undergoes a programmed contraction that leaves a population of memory CD8 + T cells that persist after resolution of the infection. Upon the second encounter with their specific antigens, memory CD8 + T cells rapidly divide, immediately exert their effector functions and give rise to a large population of secondary effectors (3) .
Memory CD8 + T cells are divided roughly into central memory and effector memory subsets, which possess different capacities to home to lymphoid or non-lymphoid tissues, to proliferate in response to antigens or cytokines and to perform effector functions (3) (4) (5) . Phenotypic classification of memory and effector CD8 + T cells has been shown to be very useful in mouse and human studies. In humans, particular expression patterns of co-stimulatory molecules CD27, CD28 and CD45RA or CD45RO are associated with naive, memory and effector functions of CD8 + T cells. Van Lier and colleagues defined two CD8
+ memory subsets based on the expression of CD45 isoforms and CD27: CD45RO + CD27 + memory cells, which lack immediate cytotoxic function, and CD45RA + CD27 À effector cells, which have low proliferative capacity and high levels of perforin (Per) and cytotoxicity (6 
CD28
À CD45RA À/+ CCR7 À CCR5 low/À effector cells by differential expression of cell surface markers and effector molecules (8) .
Chemokine receptors are also useful to discriminate naive, memory and effector subsets in the human CD8 + T cell population. For example, CCR7 is expressed on naive and memory CD8
+ T cells and acts as a receptor for homing of these cells to secondary lymphoid tissues (3, 4) . CCR5 is predominantly expressed on memory CD8 + T cells, and its expression decreases during differentiation from memory to effector T cells: CD27 À memory subsets (13) . In addition, another study demonstrated that CCR6 is expressed on human effector memory CD8 + T cells with the CD27 + CD28 + CD45RA À phenotype (14) . CCR4 is a chemokine receptor for thymus and activationregulated chemokine (TARC) and macrophage-derived chemokine (MDC) (15, 16) . It has been proposed to be a preferential marker for T h 2 cells, and thus, CCR4 and its ligands may function as regulators of T h 2 cells. CCR4 is selectively expressed on the majority of peripheral memory T h 2 cells and antigen presenting cells that produce TARC and MDC (17) . Its expression is increased in most skin-homing T h 2 cells that express cutaneous lymphocyte-associated antigen (CLA) (18, 19) . In addition to CD4 + T cells, CD8 + T cells also express CCR4 in atopic dermatitis (AD), psoriasis and adult T cell leukemia/lymphoma (19) (20) (21) (22) . In psoriasis patients, the frequencies of peripheral CD4
+ and CD8 + T cells expressing CCR4 are significantly higher than those in healthy donors, and the expression of CCR4 in epidermal T cells is even higher than that in peripheral ones (20) . These observations suggest an important role for CCR4 + CD8 + T cells in the pathogenesis of cutaneous diseases. However, the phenotype and function of human CD8 + T cells expressing CCR4 have not been clearly defined.
In the present study, we investigated the expression and function of CCR4 on human CD8
+ T cells and characterized CCR4 + CD8 + T cells. We here show that CCR4 was expressed on a part of the memory cell population and that CCR4 + CD8 + memory T cells had the ability to produce multiple cytokines including IL-4 and to migrate in response to CC chemokine receptor ligand (CCL)17/TARC and CCL22/MDC.
Materials and methods
Blood samples
Blood samples were taken from healthy adult individuals. For analysis of EBV-specific and human cytomegalovirus (HCMV)-specific CD8 + T cells, samples were obtained from EBV-seropositive individuals with HLA-A*1101 and those with HLA-A*0201, respectively. Kumamoto University Ethical Committee approval was received for this study including HLA DNA typing, and the informed consent of all participating subjects was obtained.
Antibodies
Antibodies were obtained from BD Biosciences (San Diego, CA, USA) except for the following ones: FITC-labeled anti-CD3 mAb was purchased from Dako Cytomation (Glostrup, Denmark). Energy-coupled dye (ECD)-labeled anti-CD3, ECD-labeled anti-CD45RA and ECD-labeled anti-CD28 mAbs were obtained from Immunotech (Marseille, France). Cascade Blue-labeled/Cascade Yellow-labeled anti-CD8 mAbs were prepared by conjugating anti-CD8 mAb with Cascade Blue and Cascade Yellow (Molecular Probes, Eugene, OR, USA), respectively.
HLA-class I tetramer
HLA-class I-peptide tetrameric complexes (tetramers) were synthesized as previously described (23 + T cell population, we stained PBMC with anti-CCR4 mAbs for 30 min at RT. Subsequently, they were washed with PBS/10% NCS and stained with anti-CD27, anti-CD28, anti-CD45RA and anti-CD8 mAbs for 30 min at 4°C followed by two washes with PBS/10% NCS. PE-labeled mouse IgG was used as negative control. The percentage of CCR4 + cells in each subset was measured by using an LSR II flow cytometer (BD Biosciences).
To determine CCR7, CCR6 and CCR5 expression on the CCR4 + CD8 + T cell population, we stained PBMC with anti-CCR7, anti-CCR6, anti-CCR5 and anti-CCR4 mAbs for 30 min at RT. After the cells had been washed with PBS/10% NCS, they were then stained with anti-CD8 mAb for 30 min at 4°C. FITC-, PE-, PE Cy7-and allophycocyanin (APC)-labeled mouse IgGs were used as negative controls.
For determination of CCR4 expression in the CCR7CCR5 subset in each CD27CD28CD45RA subset, PBMC were stained with anti-CCR7, anti-CCR5 and anti-CCR4 mAbs for 30 min at RT. They were subsequently washed with PBS/ 10% NCS and then incubated with anti-CD27, anti-CD28, anti-CD45RA and anti-CD8 mAbs for 30 min at 4°C. Stained cells were analyzed by use of the LSR II flow cytometer. FITC-, PE-and PE Cy7-labeled mouse IgGs were used as negative controls.
To examine the intracellular expression of Per, granzyme (Gra) A and GraB in CCR4 + , CCR7 + and CCR6 + subsets of CD27 high/low CD28 4°C for 10 min with PBS containing 0.1% saponin and 20% NCS (permeabilizing buffer) and thereafter washed with the permeabilizing buffer. After having been stained with antiPer and anti-GraA mAbs or anti-GraA and anti-GraB mAbs at 4°C for 30 min, they were finally washed three times in the permeabilizing buffer at 4°C. FITC-, PE-, PE Cy7-and APC-labeled mouse IgGs were used as negative controls.
To clarify the expression of CCR4 on EBV-and HCMVspecific CD8
+ T cells, we incubated PBMC with EBV-A*1101 and HCMV-A*0201 tetramers for 30 min at 37°C. The cells were washed twice with RPMI/10% NCS and then stained with anti-CCR5 and anti-CCR4 mAbs for 30 min at RT. After having been washed with PBS/10% NCS, the cells were stained anti-CD27, anti-CD28, anti-CD45RA and anti-CD8 mAbs for 30 min at 4°C. The percentage of CCR4 + cells in each subset was measured by using the FACSAria TM .
Cytokine production by CCR4 + and CCR7 + subsets of CD45RA
To measure cytokine production by CCR4 + and CCR7 + subsets of CD45RA À
CD8
+ T cells, we purified CD8 + T cells from PBMC by using anti-CD8-coated magnetic beads (Miltenyi Biotec, Gladbach, Germany). The purified CD8
+ T cells (>98%) were stained with anti-CD45RA, anti-CD8 and either anti-CCR4 or anti-CCR7 mAbs, and then CCR4 + CD45RA À CD8 + and CCR7 + CD45RA À CD8 + T cells were separated by a cell sorter (FACSAria; BD Biosciences, San Jose, CA, USA). The sorted T cell subsets were cultured for 6 h in F-bottom 96-well plates with or without phorbol myristate acetate (PMA) (10 ng ml
in RPMI containing 10% FCS (R10 medium) in the presence of brefeldin A (10 lg ml À1 ). The cells were fixed with 4% PFA at 4°C for 20 min and then permeabilized at 4°C for 20 min. Next, they were re-suspended in the same buffer and stained with anti-IFN-c, anti-IL-2, TNF-a and IL-4 mAb at RT for 30 min. Thereafter, they were washed three times in the permeabilizing buffer at 4°C. We also used FITC-, PE-, PE Cy7-and APC-labeled mouse IgGs for isotype controls. The cells were finally re-suspended in PBS containing 2% PFA, and the cytokine profile was analyzed by using a FACSAria.
Migration assay
The chemotaxis was measured by a TAXIScan holder (Effector Cell Institute, Tokyo, Japan) as previously described (26) . Chemokines used in this study were 100 lg ml À1 of human recombinant TARC, 50 lg ml À1 of human recombinant MDC and 100 lg ml À1 stem cell factor (SDF)-1a (PeproTech House, London, UK). A glass plate was coated with RPMI/ 40% FCS before assembly of the TAXIScan chamber. After 180 min, we counted the number of sorted cells that had migrated toward the middle of the channel by using a TAXIScan analyzer (Effector Cell Institute).
Results
Functional expression of CCR4 on human memory CD8 + T cells
We first investigated the surface expression of CCR4 on CD8 + T cells from 15 healthy individuals by using anti-CD8, anti-CD3 and anti-CCR4 mAbs. A representative result of flow cytometric analysis is shown in the left panel of Fig. 1 (A). The expression of CCR4 varied among the 15 individuals, ranging from 0.6 to 4.8% (mean 6 SD, 2.3 6 1.5%; Fig. 1A ) of the total CD8 + T cell population. These results suggest that a limited number of CD8 + T cells expressed CCR4 in a given CD8 + T cell subset. A previous study showed that CD8 + T cells could be classified into naive cells, memory cells, effector memory cells and effector cells based on the expression patterns of three cell surface markers, i.e. CD27, CD28 and CD45RA (6, 7, 9) . To identify populations expressing CCR4, we investigated the surface expression of CCR4 in each CD27CD28CD45RA subset of CD8 + T cells. PBMC were isolated from seven healthy donors and then analyzed by flow cytometry after staining with anti-CCR4, anti-CD8, anti-CD45RA, anti-CD27 and anti-CD28 mAbs. A representative result is shown in Fig. 1(B effector memory phenotype and the ability to kill the target cells (9, 10). Our previous study showed that EBV-and HCMV-specific CD8 + T cells in the peripheral blood expressed CCR5, but neither CCR7 nor CCR6 (14) . It implied that EBV-specific CD8 + T cells would express CCR4 and HCMV-specific ones would not. Therefore, we next analyzed the expression of CCR4 on EBV-and HCMV-specific CD8 + T cells. The representative result was shown in Fig.  1 
(D). EBNA3B-and HCMV-specific CD8
+ T cells did not express CCR4, whereas these subsets predominantly express CCR5. We also investigated the CCR4 expression on EBV-specific CD27
+ T cells and HCMVspecific CD27
cells by eight-color flow cytometry. Each subset of EBV-and HCMV-specific CD8
+ T cells did not express CCR4 (data not shown). These results indicate that EBV-specific CD8
À memory phenotype. CCR7 and CCR5 are predominantly expressed on naive and central memory CD8
+ T cells and on effector memory ones, respectively (9, 10), whereas CCR6 was shown to be expressed on early effector memory CD8 + T cells (14) . To examine the correlation between the expression of CCR4 and that of the other three receptors, we next investigated the co-expression of CCR4 and CCR7, CCR6 or CCR5 on CD8 + T cells from six healthy donors. A representative result of flow cytometric analysis is shown in Fig. 2(A) . The result subjects showed that 25.0 6 9.8 and 40.6 6 9.6% of the Function of human CCR4 + CD8 + T cells 525 
CD8
+ T cells are predominantly found in the effector memory T cell population (9, 10) . To better understand the differentiation state of CCR4 + CD8 + T cells in the CD27 + CD28 + CD45RA À memory subset, we analyzed the PBMC from five healthy individuals by seven-color flow cytometric analysis with anti-CCR4, anti-CCR5, anti-CCR7, anti-CD27, anti-CD28, anti-CD45RA and anti-CD8 mAbs. A representative result is shown in Fig. 2(B) . The results from five subjects showed that 45. 2 
+ T cell population were sorted from the PBMC of healthy individuals and examined for their migration activities in response to TARC, MDC and SDF-1 (Fig. 3) + subset expressed GraA and a low level of Per (Fig. 4A) . Similar results were also found for the CD27 low CD28
+ CD45RA À memory population. We further analyzed GraB expression and found that the CCR4 + subset of CD27 + CD28 + CD45RA À CD8 + T cells did not express GraB (data not shown). These results were confirmed with an experiment using the PBMC from two other individuals (Fig. 4B) + ones producing these cytokines. Similar results were found in the analysis of four individuals, though a significant difference in TNF-a and IL-4 production was found between the CCR4 + and CCR7 + subsets (Fig. 5B) .
To examine the combinations of cytokines produced by CCR4 + CD45RA
À CD8 + cells, we analyzed the production of four cytokines by U-26 PBMC by using seven-color flow cytometry with anti-CD45RA, anti-IFN-c, anti-IL-2, anti-TNF-a, anti-IL-4, anti-CD8 and anti-CCR4 or anti-CCR7 mAbs. 528 Function of human CCR4 + CD8 + T cells Fig. 5C and D) . The same results were found in a different experiment using memory T cells from other individuals (data not shown). These data indicate that CCR4 +
+ cells were memory subsets having the ability to produce multiple cytokines including type 2 ones.
Discussion
Phenotypic classification of human CD8
+ T cells is necessary to investigate the differentiation of human memory CD8
+ T cells and to analyze cell-mediated immunity in various diseases (6) (7) (8) . Previous studies revealed that human memory CD8
+ T cells can be characterized by the 
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À phenotype (7, 8, 10) , though early study showed that surface expression of CCR7 discriminates central memory (CCR7 + CD45RA À ) from effector memory (CCR7 À CD45RA À ) subsets (4) . Although these surface markers are useful tools for the phenotypic classification of the human memory CD8 + T cells, there seems to be no clear consensus regarding the pathway of central/effector memory T cell differentiation. Studies using ex vivo phenotypic analysis of human CD8 + T cells in viral infections (7) (8) (9) suggest that the CCR7 (10, 29) but that HCMVspecific CD8 + T cells express both effector memory and effector phenotypes (30) . Therefore, we speculate that EBVspecific CD8 + T cells expressed CCR7, CCR6 or CCR4. Our previous study showed that EBV-specific CD8 + T cells in the peripheral blood expressed neither CCR7 nor CCR6 (14) . In the present study, we found no expression of CCR4 on EBVspecific CD8 + T cells in the peripheral blood (Fig. 1D) . These results together indicate that the EBV antigen-specific CD8 + T cells were not only central memory CD8
+ T cells but also early effector memory CD8 + T cells. Our present study demonstrated the effective migration of CCR4 + memory CD8 + T cells in response to TARC and production of IFN-c and TNF-a in these cells. CCR4 and its ligand TARC are involved in lymphocyte-endothelial interactions during lymphocyte recruitment to normal and inflamed cutaneous sites (18, 31) . A previous study using the human HaCaT cell line as a model for human keratinocytes showed that these cells produced TARC in response to IFN-c or TNF-a (32) . An in vivo study using NC/Nga mice as a model for human AD confirmed that TARC was produced mainly by the keratinocytes in the basal layer of the skin, whereas MDC was produced by dermal DCs (33). In extrinsic AD patients, most of CLA + CD8 + T cells express CCR4 (19) . These results suggest the possibility that CCR4 + CD8 + T cells can migrate into the secondary lymphoid organs, and they mature after interacting with DCs expressing CCR4 ligand. These matured CCR4
+ CD8 + T cells may migrate into inflamed skin and secrete IFN-c and TNF-a, which cytokines then induce TARC and MDC production by the keratinocytes and dermal DCs. Finally, these TARC and MDC ligands enhance the migration of a number of T h 2 cells to the site of inflammation. Thus, we assume that CCR4 + memory CD8 + T cells would play an important role in the pathogenesis of AD.
In summary, we showed that CCR4 + CD8 + T cells had the characteristics of memory subsets secreting type 1 and type 2 cytokines but not expressing effector molecules and that the expression of CCR4 was down-regulated during the differentiation of human memory CD8 + T cells. The expression pattern of this receptor, together with that of other chemokine receptors, is shown in Fig. 6 . It is useful for functional classification of human memory T cells. The classification of memory CD8 + T cell subsets using the expression pattern of these chemokine receptors will help to clarify the differentiation and maturation pathway of human memory T cells. 
